BCL2 and cancer: Furthermore, for mice, the therapeutic performance of co-delivered siRNA/DOX@Ca2+ MSNs significantly increased tumor suppression more than DOX@MSNs and siRNA@Ca2+ MSNs, causing the transfected cancer cells to become sensitized to the apoptotic action of co-delivered DOX by Bcl-2 silencing [148].